Debut Plus

BSE · 544673

Modern Diagnostic & Research Centre Ltd.

77.07
market cap
P/E
EPS
₹—
Book value
₹—
ROE
ROCE
Debt / equity
1.31

Revenue & net profit by period

Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.

019.739.459.178.8Mar 22Mar 23Mar 24Mar 25
Revenue (₹ Cr) Net profit (₹ Cr)

Latest period: revenue ₹79 Cr with net profit ₹9 Cr — a 11.38% net margin, versus 8.44% the period before.

Shareholding

As of 2026-03-31

72.85%
promoter holding
  • Promoter72.85%
  • Public11.64%
  • FII0.03%
  • DII15.48%

282 shareholders on record

Promoter holding trend

Each disclosed period, oldest to newest

100%72.85%Mar 25Mar 26

52-week position

Where the current price sits in its yearly band

4577.07100

The band spans 2.22× from low to high.

Risk flags

Derived from disclosed data

No flags raised by the data.

Peer comparison

Healthcare · ranked #1 of 85 by market cap · medians across 50 industry peers

P/E
vs 47.12 peer med
P/B
vs 5.7 peer med
ROE %
vs 12.56 peer med
Margin %
vs 11.78 peer med
CompanyMkt capP/EP/BROEMargin
Apollo Hospitals Enter. Limited₹1,27,048 Cr60.3813.4220.48%7.91%
Max Healthcare Institute Ltd.₹1,01,000 Cr67.479.413.42%16.73%
Manipal Health Enterpri Limited₹94,359 Cr100.615.7310.59%7.81%
Fortis Healthcare Ltd.₹67,025 Cr62.836.7710.53%11.02%
Aster DM Quality Care Ltd.₹66,652 Cr171.8315.818.48%6.54%
Global Health Limited₹38,911 Cr67.989.8214.05%11.88%
Narayana Hrudayalaya Ltd.₹38,199 Cr44.318.4117.76%9%
Krishna Institute of Medical Sciences Ltd.₹32,296 Cr154.728.6210.74%4.85%
Dr. Lal Path Labs Ltd.₹32,042 Cr56.9712.7820.13%18.75%
Poly Medicure Ltd.₹17,613 Cr55.045.6710.37%15.77%
Modern Diagnostic & Research Centre Ltd.(this company)

AI analysis

AI-generated · google/gemini-2.5-flash

Modern Diagnostic & Research Centre Ltd. has not specified its business activities. The company's 52-week high is Rs 100 and its 52-week low is Rs 49.

Positives

  • +Revenue increased by 14.86% to Rs 78.8045 Cr in March 2025.
  • +Net profit grew by 54.76% to Rs 8.9681 Cr in March 2025.
  • +Promoter holding is high at 72.8514% as of March 31, 2026.
  • +No promoter shares are pledged as of March 31, 2026.

Negatives

  • The debt-to-equity ratio is 1.31.
  • FII shareholding decreased to 0.0318% as of March 31, 2026, from 1.0703% as of January 31, 2026.
  • Public shareholding decreased to 11.6352% in March 2026 from 14.2737% in January 2026.
  • The number of shareholders decreased from 641 in January 2026 to 282 in March 2026.

Financial performance

The company's revenue increased by 14.86% to Rs 78.8045 Cr in March 2025, from Rs 68.672 Cr in March 2024. Net profit grew by 54.76% to Rs 8.9681 Cr in March 2025, compared to Rs 5.7948 Cr in March 2024. EBITDA also saw a growth of 68.76% to Rs 14.6319 Cr in March 2025 from Rs 8.6704 Cr in March 2024.

Profitability & returns

Modern Diagnostic & Research Centre Ltd. reported an earnings per share (EPS) of Rs 8.15 in March 2025, an increase from Rs 5.27 in March 2024. This follows a period of negative EPS, with -Rs 5.21 in March 2023 and -Rs 1.32 in March 2022.

Balance sheet

The company has a debt-to-equity ratio of 1.31.

Ownership & pledges

As of March 31, 2026, promoters held 72.8514% of the company. Institutional investors, including DIIs and FIIs, collectively held 15.5134% of the shares. Public shareholding was 11.6352%. There were no promoter shares pledged as of March 31, 2026.

Regulatory & surveillance

No information regarding surveillance measures for Modern Diagnostic & Research Centre Ltd. was available in the provided data.

Data as of — price: 2026-09-12 · financials: Mar 25 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.

How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.

Back to Modern Diagnostic & Research Centre Ltd.share price & fundamentals